Andere talen Cue Biopharma, Inc.

Aandelen

CUE

US22978P1066

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,365 ^USD	-3,19%		-12,50%	-48,30%

08/04	Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
28/03	Cue Biopharma, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights	08/04
North American Morning Briefing : Inflation Data, -2-	08/04
Cue Biopharma to Host Business Update Call and Webcast	02/04
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
North American Morning Briefing : Tech in Focus on -2-	25/03
North American Morning Briefing : Investors -2-	18/03
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium	29/02
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	23/11
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit	22/11
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights	09/11
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	07/11
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	07/11
Cue Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11
Cue Biopharma Reports Prolonged Survival in Phase 1 Trials of CUE-101; Shares Climb	03/11
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023	03/11
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and Cue-102 in Wilms' Tumor 1 Positive Cancers at SITC 2023	03/11
Cue Biopharma to Host Business Update Call and Webcast	02/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cue Biopharma, Inc.

Aandelen

CUE

US22978P1066

Andere talen

Filters